Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system.
OBJECTIVE
Obesity has been implicated in the aetiology of myelogenous leukaemia and myelodysplasia (MDS). We hypothesised that altered secretion of adiponectin and resistin may underlie this association. We thus investigated the role of both total and high molecular weight (HMW) adiponectin and resistin in MDS.


METHODS
In a case-control study, we studied 101 cases with incident, histologically confirmed primary MDS and 101 controls matched on gender and age between 2004 and 2007. Total and HMW adiponectin, resistin, insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein (IGFBP-3) were determined.


RESULTS
Lower serum total or HMW adiponectin and/or resistin levels were independently associated with higher risk of MDS controlling for age, gender, BMI and serum levels of leptin, IGF-I and IGFBP-3 (p<0.002). Although total and HMW adiponectin were both significantly inversely associated with MDS when modelled either in quartiles or continuously, HMW did not offer any substantial additional predictive value over total adiponectin (Odds ratio (OR)=0.91 versus 0.93 for a 1 microg/ml change, respectively). IGF-I was positively associated with MDS by bivariate analysis and both IGF-I and IGFBP-3 were higher in advanced MDS and higher risk stages, but were not significantly and independently associated with MDS.


CONCLUSIONS
Total and HMW adiponectin may have a protective role in MDS, whereas resistin levels may be decreased via a compensatory mechanism.
Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, Chaidari, Athens, Greece.
Maria
M
Dalamaga
Konstantinos
K
Karmaniolas
Athina
A
Nikolaidou
John
J
Chamberland
Alex
A
Hsi
Amalia
A
Dionyssiou-Asteriou
Christos S
CS
Mantzoros
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood* / Q000517:prevention & control; D009765:Obesity / Q000097:blood; D016017:Odds Ratio; D011237:Predictive Value of Tests; D052243:Resistin / Q000097:blood*; D012307:Risk Factors; D012680:Sensitivity and Specificity
D052242:Adiponectin; D018969:Insulin-Like Growth Factor Binding Proteins; D052243:Resistin; D007334:Insulin-Like Growth Factor I